European Biotech Hiring in 2026: The roles in demand and how to get into them

If you are a mid-career life sciences professional wondering whether now is the moment to make a move, this piece gives you the honest picture of what is in demand, where the real shortages sit, and what to do about it before the rest of the market catches on.

Below are six moves we think every mid-career professional in the Dutch, Belgian, and Swiss markets should be making in 2026. They are informed by what we see across hiring processes every day, which roles are moving, which packages are clearing, and where candidates are leaving leverage on the table.

To understand 2026, it helps to understand what the previous two years actually were. The pullback in hiring that started in 2023 was real, but it was uneven. Large pharma companies that had over-expanded during the COVID-era hiring surge trimmed headcount. Some mid-sized biotechs, caught between valuations and a tighter funding environment, went quiet. That created a genuine surplus of talent at certain levels, particularly in early-stage research and parts of commercial, which gave the market a misleading appearance of ease.

Underneath that, the structural story never changed. Certain specialisms, such as process development, GMP manufacturing, regulatory affairs, applied bioinformatics, and ATMP manufacturing, have never had excess supply to give back. The professionals working in those areas will have noticed: the calls did not stop, the rates held, the opportunities did not dry up.

What is happening now is that the rest of the market is catching up with that underlying reality. Pipelines that were paused are advancing. Capital that sat on the sidelines through 2024 is deploying. The EU's 2030 life sciences strategy, backed by more than €10 billion per year, is reshaping expectations for compliance and manufacturing across the value chain. And the Dutch government's €1.3 billion commitment to position the Netherlands as a global biotech leader by 2040 is translating into genuine cluster growth, particularly in cell and gene therapy.

The hiring acceleration projected for late 2025 is materialising. It is doing so in a way that rewards specialisation, and it is doing so unevenly across the year.

The demand is real, but it is narrow. From what we see across hiring processes, urgent shortages are concentrated in five areas.

ATMP and next-generation therapeutics manufacturing is the sharpest of them. Cell and gene therapy attracted enormous investment globally through 2025, and the gap between that capital and the people who can actually execute in GMP ATMP environments is significant. Both the Netherlands, with hubs at Leiden, Utrecht, and Amsterdam's AMC ecosystem, supported by national platforms like DARE-NL and Switzerland, where Novartis's Stein facility and a growing cluster of CDMOs sit, are actively competing for a very small pool of people with hands-on ATMP manufacturing, process characterisation, or quality oversight experience.

Regulatory affairs and QA/compliance continue to be the thread running through every senior hiring conversation we have. The European regulatory environment is genuinely complex right now: IVDR transitions are still creating pressure, EMA's post-Brexit consolidation in Amsterdam has increased the volume and visibility of regulatory interaction, and the EU's 2030 strategy is repricing compliance expertise across the value chain. Senior regulatory leads with ATMP, oncology, or novel biologics experience are exceptionally hard to find in either market.

Process development and biomanufacturing scale-up have quietly become one of the most in-demand groups in European life sciences. A wave of molecules that entered clinical development two to four years ago is approaching commercial scale, and the technical transfer capability to move them from lab to GMP manufacturing is in short supply, particularly in Switzerland's complex biologics and fill-finish operations across Roche, Novartis, and high-spec CDMOs.

Applied bioinformatics and computational biology are in demand, but with a nuance. The shortage is not for bioinformaticians in the abstract. It is for those who can function within biotech and pharma timelines, building pipelines that support drug discovery decisions, integrating multi-omics datasets, or running biomarker analyses within clinical development teams. The computational scientist who has moved beyond academia into industry is genuinely scarce.

Clinical data and statistical programming are the least glamorous of the five, but the most consistent in demand. CDISC-proficient data managers and statistical programmers, particularly those with oncology or rare-disease experience, are commanding higher rates, especially in the Netherlands contractor market.

What to do next?
If you sit cleanly in one of these areas, lead with that specialism in every conversation, application, and recruiter introduction. Do not soften it with broader framing; the value is in the specificity. If you are adjacent, for example, you have strong GMP foundations in biologics and want to move into viral vectors or ATMP, start mapping the transition explicitly: which adjacencies translate, which certifications signal readiness (PDA, GMP-trained, RAC, ECA), and which roles serve as a bridge. The companies hiring in these areas are not training generalists; they are hiring people who can already do the work.

The risk if you do not?
If you describe yourself as a generalist with a side of specialism, hiring teams will read you that way. In a market where people are leading with exactly the specialism the company needs, "well-rounded" is not the asset you think it is.

This is the move we see the most professionals getting wrong. The 2023–2024 slowdown affected generalist roles and functions where supply genuinely did exceed demand, early-stage research, some commercial roles, and certain operations functions. It did not touch the specialist niches above. Rates held throughout. In several areas, they moved up.

The ranges below reflect what we are seeing for mid- to senior-level roles (typically 5–10 years of relevant experience) in biotech and mid-sized pharma in 2026.

Base salary ranges in EUR (Netherlands, Belgium) and CHF (Switzerland). Global pharma typically sits at the upper end; smaller biotechs at the lower end, but often with equity. Switzerland's packages reflect cost-of-living parity. Contractor day rates frequently exceed annualised permanent rates in process development, regulatory, and clinical data.

What to do now
Before any salary conversation, internal review, counteroffer, or new role, benchmark your current package against these ranges. If you are sitting 10–15% below where the market is for your specialism, you have leverage you are probably not using. If compensation is the primary driver behind a potential move, contracting in Switzerland or the Netherlands often pays a meaningful premium over permanent for the same scope of work.

The risk if you do not?You carry expectations into negotiations that reflect 2023, not 2026. The market is currently willing to pay more than many candidates are willing to ask for. That gap is yours to close.

This is the single most common limitation we see in candidate behaviour, and it is costing people meaningful opportunities.

In specialisms where the talent pool can be measured in the low hundreds across a region, no employer's first move is to put a job ad up and wait. They reach out to specialist recruiters, they tap their network, they make direct approaches. The roles that matter most in 2026, particularly at the senior and director levels, are being filled this way.

What to do now
Treat the public market as roughly a third of what is available to you. Make yourself visible to one or two specialist life sciences recruiters who work in your region and your discipline (we would argue for that, but it is true either way). Have a clear view of your CV, your salary expectations, and the specific roles you are open to, not a vague "I am exploring" position. The candidates who get the call when something interesting comes up are the ones recruiters can put a face on, not the ones submitting applications.

The risk if you do not?
You compete only for the most visible roles and against the largest, least differentiated pool of candidates. The roles that would have been the best fit for you may pass you entirely.

The Netherlands, Belgium, and Switzerland are not the same market, and the choice between them matters in ways beyond salary.

The Netherlands, particularly the Leiden–Amsterdam–Utrecht axis, is where you are most likely to find early-to-mid-stage biotech opportunities with real upside: equity, proximity to clinical programmes, and ,the chance to shape functions from a relatively early stage. The Dutch government's €1.3 billion commitment to make the country a global biotech leader by 2040 is translating into genuine cluster growth, particularly in cell and gene therapy, where DARE-NL and investments from BMS, Kite, Lonza, and Fujifilm in Leiden have created one of Europe's densest ATMP ecosystems.

Switzerland is where you go for scale, compensation, and programme complexity. The Roche and Novartis campuses, alongside a dense cluster of CDMOs and mid-sized precision medicine companies in the Basel–Zürich corridor, offer something different: programmes that are further along, manufacturing infrastructure that is genuinely world-class, and packages that remain the highest in European life sciences. Scientist vacancies were up 4.7% in 2025, with Basel hiring forecast to grow 8.6% this year.

Belgium, particularly the Antwerp–Ghent and Wallonia corridors, sits between the two: real scale in biomanufacturing (the J&J, GSK, and UCB footprint), proximity to the Dutch ATMP ecosystem, and a contractor-friendly market for regulatory, QA, and clinical roles.

What to do now
Do not drift into the most familiar geography. Map your priorities: equity upside, compensation ceiling, programme stage, ecosystem density, language, lifestyle and target deliberately. The same person can have meaningfully different career trajectories in Leiden versus Basel.

The risk if you do not?
You optimise for the easiest move rather than the right one. Five years on, that compounds.

The most sought-after candidates we place in 2026 are not the ones with the deepest single-discipline expertise. They are the ones who sit at the intersection of two: scientific domain knowledge plus a second capability. Domain plus data. Domain plus regulatory. Domain plus manufacturing. Domain plus computational.

These intersections are where the structural shortages sit, because the people who genuinely combine both are rare, and the demand is high. But many candidates who fit this profile undersell themselves, describing it apologetically, as if they do not "fit neatly into one box."

What to do now
Reframe the combination as a specific, named profile rather than a hybrid identity. "Bioprocess scientist with hands-on ATMP scale-up and CMC regulatory experience" is a profile that companies actively recruit for. "I sit between manufacturing and regulatory" is not. The work is the same; the framing determines whether the right hiring manager finds you.

The risk if you do not?
You get filtered out at the CV stage as a generalist, even though you are actually a sought-after intersection. The system rewards specificity.

Move 6: Start the conversation before the squeeze tightens
Hiring acceleration is underway, but it is not evenly distributed throughout the year. Companies that wait until Q2 or Q3 of 2026 to begin recruiting will be competing with every other organisation hitting the same pipeline phase transitions. Candidates who move in Q1 and early Q2 face fewer competing applicants and longer, more deliberate processes; those who wait until later in the year encounter compressed timelines, more competition for the same roles, and reduced negotiating leverage on packages.

What to do now
If you are seriously considering a move in 2026, begin conversations now, not in May, not after the summer. That does not mean committing. It means being in front of recruiters and hiring teams while the pipeline is wide. Companies are currently willing to spend time on the right candidate. By mid-year, when the squeeze tightens, that patience compresses.

The risk if you do not?
When everyone moves at once, leverage compresses. The same offer that would clear with three weeks of negotiation in Q1 can become take-it-or-leave-it in Q3.

European biotech hiring in 2026 is not a broad recovery. It is a concentrated, urgent return of demand in a handful of disciplines where the shortfall between supply and demand is genuinely acute. ATMP manufacturing, regulatory affairs, process development, applied computational biology, and clinical data sit at the centre of it.

If you're mid-career in these fields, you really do have an edge - but it won't work on its own. You have to be intentional about how you present yourself, what you ask for, where you search, and when you make your move.

The professionals who get the most out of 2026 will be the ones who read the market accurately and act before the rest catch up. The professionals who underperform will be the ones still reading in 2024. You'll win in 2026 by reading the market right and acting early. You'll lose by sticking to how things worked two years ago.